Psychiatry & Neurology Doctors in Boerne, TX Accepting Medicare

4 Psychiatry & Neurology doctors found. Showing 1 - 4

Dr. Martha Medrano, M.D. Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 430 W Bandera Rd Ste 9, Boerne, TX 78006 Phone: 210-233-7000    Fax: 210-434-1704

Dr. Julia Christine Jackson, M.D. Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 26254 Interstate 10 W Ste 140, Boerne, TX 78006 Phone: 210-455-0444    Fax: 830-255-5966

Lauren Catherine Skalomenos, MD Psychiatry & Neurology - Neurology Medicare: Medicare Enrolled Practice Location: 25723 Old Fredericksburg Rd, Boerne, TX 78015 Phone: 210-450-6800

Dr. Zarghoona Khalil Ullah, MD Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 27511 Interstate 10 W Bldg 5, Boerne, TX 78006 Phone: 830-340-1100    Fax: 210-352-5205

News Archive

Computer-generated flu vaccine enters clinical trials in the US

A seasonal flu vaccine that has been developed entirely by artificial intelligence on a computer is set to be tested in clinical trials in the US.

Antihypertensive drugs are not linked to cancer, shows study

There is no evidence that blood pressure lowering drugs increase the risk of cancer, according to the most extensive study conducted on the topic. The late breaking research is presented today at ESC Congress 2020.

Leatt sues Atlas for infringement on two neck brace patents

Leatt Corporation, a global developer, marketer and the distributor of the Leatt-Brace, a neck brace system designed to help prevent potentially devastating injuries to the cervical spine (neck) for helmeted sports, announced today that the Company has sued Atlas Brace Technologies US, LLC for infringement on two of the Company's neck brace patents.

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

Study finds racial disparities among children with Crohn's disease

A study published recently in the IBD Journal found significant differences in hospital readmissions, medication usage, and both medical and surgical complications of children with Crohn's disease related to race. In the study, black children had a 1.5 times higher frequency of hospital readmissions because of Crohn's disease compared to white children.

Read more Medical News

› Verified 8 days ago